Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
|
|
- Roderick Gervase Webster
- 5 years ago
- Views:
Transcription
1 Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program Duke Cancer Institute
2 Disclosures Jeffrey Crawford, MD Scientific Advisor: AstraZeneca, Merck, Pfizer DSMB Member: Beyond Spring, Celgene, G1 Therapeutics, Janssen, Merrimack, Mylan, Roche Principal Investigator/Institutional Research Funding: Amgen, AstraZeneca, Bayer
3 Introduction Limited randomized data of chemotherapy and immunotherapy Keynote 21G, randomized phase II trial of carboplatin and pemetrexed +/- pembrolizumab in Stage IV NSCLC 1,2 Pacific trial, randomized placebo controlled phase III trial of durvalumab after chemoradiotherapy in Stage III NSCLC 3,4 1 Langer CJ, et al. Lancet Oncol. 2016;17(11): Borghaei H. ESMO, Paz-Ares L. ESMO Antonia S. NEJM, 2017, 377:
4 4
5 Cohort G of the KEYNOTE-021 study (ClinicalTrials.gov, NCT ) was an open-label, randomized phase 2 trial of pembrolizumab plus pemetrexed-carboplatin (PC) vs PC alone in patients with previously untreated advanced nonsquamous NSCLC Primary analysis (minimum 6-month follow-up; median, 10.6 months) 1 Significant improvements in ORR (55% vs 29%; P = ) and PFS (HR, 0.53; P = 0.010) HR for OS, 0.90 (P = 0.39) ASCO updated analysis (median follow up, 14.5 months) 2 Improvements in ORR and PFS maintained HR for OS, 0.69 (P = 0.13) KEYNOTE-021 Cohort G Manageable safety profile in both analyses Pembrolizumab plus pemetrexed-carboplatin has received accelerated approval from the U.S. Food and Drug Administration for treatment of first-line nonsquamous NSCLC This presentation reports updated efficacy/safety with 5 additional months of follow-up (median, 18.7 months) 1. Langer CJ, et al. Lancet Oncol. 2016;17(11): Papadimitrakopoulou VA, et al J Clin Oncol. 35(suppl): abstract 9094.
6 Study Population Untreated stage IIIB or IV nonsquamous NSCLC No activating EGFR mutation or ALK translocation Provision of a sample for PD-L1 assessment a ECOG PS 0 or 1 No untreated brain metastases No ILD or pneumonitis requiring systemic steroids KEYNOTE-021 Cohort G R (1:1) a N = 123 Pembrolizumab 200 mg Q3W for 2 years + Pemetrexed 500 mg/m 2 + Carboplatin AUC 5 mg/ml/min Q3W for 4 cycles Pemetrexed 500 mg/m 2 + Carboplatin AUC 5 mg/ml/min Q3W for 4 cycles End Points Primary: ORR (RECIST v1.1 per blinded, independent central review) Key secondary: PFS Other secondary: OS, safety, relationship between antitumor activity and PD-L1 TPS No alpha allocated for updated analysis; all P values are nominal (one-sided P < 0.025) a Randomization was stratified by PD-L1 TPS <1% vs 1%.
7 Study Population Untreated stage IIIB or IV nonsquamous NSCLC No activating EGFR mutation or ALK translocation Provision of a sample for PD-L1 assessment a ECOG PS 0 or 1 No untreated brain metastases No ILD or pneumonitis requiring systemic steroids KEYNOTE-021 Cohort G R (1:1) a N = 123 Pembrolizumab 200 mg Q3W for 2 years + Pemetrexed 500 mg/m 2 + Carboplatin AUC 5 mg/ml/min Q3W for 4 cycles Pemetrexed 500 mg/m 2 + Carboplatin AUC 5 mg/ml/min Q3W for 4 cycles End Points Primary: ORR (RECIST v1.1 per blinded, independent central review) Key secondary: PFS Other secondary: OS, safety, relationship between antitumor activity and PD-L1 TPS No alpha allocated for updated analysis; all P values are nominal (one-sided P < 0.025) Pemetrexed 500 mg/m 2 Q3W permitted as maintenance therapy a Randomization was stratified by PD-L1 TPS <1% vs 1%.
8 Study Population Untreated stage IIIB or IV nonsquamous NSCLC No activating EGFR mutation or ALK translocation Provision of a sample for PD-L1 assessment a ECOG PS 0 or 1 No untreated brain metastases No ILD or pneumonitis requiring systemic steroids KEYNOTE-021 Cohort G R (1:1) a N = 123 Pembrolizumab 200 mg Q3W for 2 years + Pemetrexed 500 mg/m 2 + Carboplatin AUC 5 mg/ml/min Q3W for 4 cycles b Pemetrexed 500 mg/m 2 + Carboplatin AUC 5 mg/ml/min Q3W for 4 cycles b End Points Primary: ORR (RECIST v1.1 per blinded, independent central review) Key secondary: PFS Other secondary: OS, safety, relationship between antitumor activity and PD-L1 TPS No alpha allocated for updated analysis; all P values are nominal (one-sided P < 0.025) PD Pembrolizumab 200 mg Q3W for 2 years PD, progressive disease. a Randomization was stratified by PD-L1 TPS <1% vs 1%. b Indefinite maintenance therapy with pemetrexed 500 mg/m 2 Q3W permitted.
9 Pembro + PC N = 60 PC Alone N = 63 Median (range) age, y 62.5 (40 77) 66.0 (37 80) Women 38 (63) 37 (59) ECOG PS 1 35 (58) 34 (54) Adenocarcinoma histology 58 (97) 55 (87) Stage IV disease 59 (98) 60 (95) Smoking status Current or former Never 45 (75) 15 (25) 54 (86) 9 (14) Stable brain metastases 9 (15) 6 (10) PD-L1 TPS <1% 1% 49% 50% Pembro, pembrolizumab. All data are n (%) unless otherwise stated. Data cut-off: May 31, Baseline Characteristics 21 (35) 19 (32) 20 (33) 23 (37) 23 (37) 17 (27)
10 ORR, % (95% CI) Confirmed ORR (RECIST v1.1 by Blinded, Independent Central Review) Pembrolizumab + PC Δ24.8% (95% CI, 7.2% 40.9%) P = a 31.7 PC Alone Compared with prespecified analysis 1 : 3 additional responses observed: 1 in pembro + PC arm 2 in PC alone arm 1 complete response developed in each arm Similar between-arm difference in ORR Similar pattern of response across PD- L1 distribution 1. Langer CJ, et al. Lancet Oncol. 2016;17(11): a P value is descriptive (one-sided P < 0.025). Data cut-off: May 31, 2017.
11 P r o g r e s s io n -F r e e S u r v iv a l, % Progression-Free Survival (RECIST v1.1 by Blinded, Independent Central Review) % 37% 52% 29% Events, n/n HR (95% CI) Pembro + PC 26/60 PC alone 40/ ( ) P = a Median (95% CI) 19.0 (8.5 NR) 8.9 ( ) N o. a t r is k T im e, m o n th s a P value is descriptive (one-sided P < 0.025). Data cut-off: May 31, 2017.
12 O v e r a ll S u r v iv a l, % Overall Survival Events, n/n HR (95% CI) N o. a t r is k Median (95% CI) NR (22.8 NR) 20.9 (14.9 NR) 77% 69% T im e, m o n th s 70% 56% a 24 additional deaths since primary analysis (pembro + PC, n = 7; PC alone, n = 17). b P value is descriptive (one-sided P < 0.025). Data cut-off: May 31, Pembro + PC 20/60 a 0.59 ( ) PC alone 31/63 a P = 0.03 b
13 Exposure and AE Summary Pembro + PC n = 59 Limited change in toxicity since last presentation of results 1 No additional fatal AEs 1 additional AE leading to discontinuation in each group PC Alone n = 62 Median (range) exposure, mo 10.1 (0 25.0) 4.9 (0 25.0) Treatment-related AEs, n (%) Any grade 55 (93) 57 (92) Grades (41) 18 (29) Leading to discontinuation 9 (15) 9 (15) Leading to death 1 (2) 2 (3) a Fatal AEs were sepsis in the pembro + PC group and one case each of pancytopenia and sepsis in the PC alone group. Data cut-off: May 31, Papadimitrakopoulou VA, et al J Clin Oncol. 35(suppl): abstract 9094.
14 Incidence, % Treatment-Related AEs With Incidence 15% Grade Pembro + PC PC alone AST, aspartate aminotransferase; ALT, alanine aminotransferase. Data cut-off: May 31, 2017.
15 Incidence, % AEs With Possible Immune Etiology Grade Pembro + PC PC alone Hypothyroidism Hyperthyroidism Pneumonitis Infusion reactions No grade 5 AEs with possible immune etiology Severe skin toxicity 0 Colitis Data cut-off: May 31, 2017.
16 Data cut-off: May 31, Treatment-Related AEs With Incidence 15% Pembro + PC n = 59 PC Alone n = 62 Adverse Event, n (%) Any Grade Grades 3 5 Any Grade Grades 3 5 Fatigue 40 (68) 2 (3) 27 (44) 0 (0) Nausea 35 (59) 1 (2) 28 (45) 0 (0) Anemia 20 (34) 7 (12) 34 (55) 9 (15) Vomiting 18 (31) 1 (2) 11 (18) 0 (0) Rash 16 (27) 1 (2) 9 (15) 0 (0) Diarrhea 14 (24) 0 (0) 9 (15) 1 (2) Decreased appetite 13 (22) 0 (0) 12 (19) 0 (0) Aspartate aminotransferase increased 11 (19) 1 (2) 8 (13) 1 (2) Constipation 11 (19) 0 (0) 6 (10) 0 (0) Dysgeusia 11 (19) 0 (0) 7 (11) 0 (0) Alanine aminotransferase increased 10 (17) 1 (2) 8 (13) 1 (2) Blood creatinine increased 10 (17) 0 (0) 4 (6) 0 (0) Neutrophil count decreased 10 (17) 4 (7) 8 (13) 2 (3) Lacrimation increased 9 (15) 0 (0) 7 (11) 0 (0)
17 AEs With Possible Immune Etiology Pembro + PC n = 59 PC Alone n = 62 Adverse Event, n (%) Any Grade Grades 3 4 Any Grade Grades 3 4 Hypothyroidism 8 (14) 0 (0) 2 (3) 0 (0) Hyperthyroidism 5 (8) 0 (0) 1 (2) 0 (0) Pneumonitis 4 (7) 1 (2) 0 (0) 0 (0) Infusion reactions 1 (2) 1 (2) 3 (5) 0 (0) Severe skin toxicity 1 (2) 1 (2) 1 (2) 1 (2) Colitis 1 (2) 0 (0) 0 (0) 0 (0) No grade 5 AEs with possible immune etiology Data cut-off: May 31, 2017.
18
19 PACIFIC: Study Design Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study Patients with stage III, locally advanced, unresectable NSCLC who have not progressed following definitive platinum-based ccrt ( 2 cycles) Durvalumab 10 mg/kg q2w for up to 12 months N=476 Co-primary endpoints PFS by BICR using RECIST v1.1* OS 18 years or older WHO PS score 0 or 1 Estimated life expectancy of 12 weeks Archived tissue was collected All-comers population 1 42 days post-ccrt R 2:1 randomization, stratified by age, sex, and smoking history N=713 Placebo 10 mg/kg q2w for up to 12 months N=237 Key secondary endpoints ORR (per BICR) DoR (per BICR) Safety and tolerability PROs *Defined as the time from randomization (which occurred up to 6 weeks post-ccrt) to the first documented event of tumor progression or death in the absence of progression. ClinicalTrials.gov number: NCT BICR, blinded independent central review; ccrt, concurrent chemoradiation therapy; DoR, duration of response; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PROs, patient-reported outcomes; PS, performance status; q2w, every 2 weeks; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization
20 Baseline Characteristics, Stratification Factors, and Prior Therapy in the Intention-to-Treat Population
21 Baseline Characteristics, Stratification Factors, and Prior Therapy in the Intention-to-Treat Population
22
23 Probability of death or distant metastasis Time to Distant Metastasis or Death by BICR (ITT) Durvalumab Placebo Time from randomization (months) No. at risk Durvalumab Placebo Stratified hazard ratio, 0.52 (95% CI, ) Two-sided P< Durvalumab Placebo Median time (95% CI), 23.2 (23.2 NR) 14.6 ( ) months BICR, blinded independent central review; ITT, intention-to-treat
24
25 Antitumor Activity in the Intention-to-Treat Population
26 Safety Summary* Durvalumab (N=475) Placebo (N=234) Any-grade all-causality AEs, n (%) 460 (96.8) 222 (94.9) Grade 3/4 142 (29.9) 61 (26.1) Grade 5 21 (4.4) 13 (5.6) Leading to discontinuation 73 (15.4) 23 (9.8) Any-grade treatment-related AEs, n (%) 322 (67.8) 125 (53.4) SAEs, n (%) 136 (28.6) 53 (22.6) Any-grade immune-mediated AEs, n (%) 115 (24.2) 19 (8.1) Grade 3/4 16 (3.4) 6 (2.6) *Two patients randomized to placebo received at least one dose of durvalumab and were considered part of the durvalumab arm for safety reporting. Safety analysis set. AE, adverse event; SAE, serious adverse event
27
28 Pneumonitis or Radiation Pneumonitis Pneumonitis (grouped terms) or radiation pneumonitis, n (%)* Durvalumab (N=475) Placebo (N=234) Any grade 161 (33.9) 58 (24.8) Grade 3/4 16 (3.4) 6 (2.6) Grade 5 5 (1.1) 4 (1.7) Leading to discontinuation 30 (6.3) 10 (4.3) Safety analysis set (all-causality). *Pneumonitis/radiation pneumonitis was assessed by investigators with subsequent review and adjudication by the study sponsor. In addition, pneumonitis, as reported in the table, is a grouped term, which includes acute interstitial pneumonitis, interstitial lung disease, pneumonitis, and pulmonary fibrosis. Two patients randomized to placebo received at least one dose of durvalumab and were considered part of the durvalumab arm for sa fety reporting.
29
30 Conclusions 1) In a randomized phase II trial in patients with advanced NSCLC, the addition of pembrolizumab was associated with improved PFS and OS, a) Associated increases in toxicity were largely Grade I/II b) Results of phase III trial are awaited 2) In a placebo, controlled phase III trial, durvalumab treatment was associated with improved PFS in patients with Stage III NSCLC after prior chemoradiotherapy a) Expected immune related toxicities were seen, along with an increase in radiation pneumonitis, predominantly Grade I/II b) Overall survival results are pending
31 Implications for Clinical Practice 1) The addition of immune checkpoint therapy in combination with chemotherapy in stage IV NSCLC or sequentially after chemoradiotherapy will be practice changing. 2) Extrapolation to other cancers should await well conducted controlled clinical trials. 3) To better understand the adverse event profile of combined strategies large phase IV trials and registries are needed.
Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationIMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationRelease Date: Sunday, October 9, :16 am EDT. Dateline City: KENILWORTH, N.J.
Published on Merck Newsroom Home (http://www.mercknewsroom.com) on 10/9/16 2:16 am EDT Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck s KEYTRUDA
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationESMO 2017 CONGRESS September 2017 Madrid, Spain. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 2017 CONGRESS Congress 8 12 September 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced
More informationKEYNOTE-407: Phase 3 Study of Carboplatin-Paclitaxel/Nab-Paclitaxel With or Without Pembrolizumab for Metastatic Squamous NSCLC
KEYNOTE-407: Phase 3 Study of Carboplatin-Paclitaxel/Nab-Paclitaxel With or Without Pembrolizumab for Metastatic Squamous NSCLC Luis Paz-Ares, 1 Alexander Luft, 2 Ali Tafreshi, 3 Mahmut Gümüş, 4 Julien
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationNew options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña
New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationMEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc
MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationImmunotherapy in NSCLC
Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January 27 217 Immunotherapy in NSCLC: Outline 1 st line as
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May
BRAND NAME Keytruda GENERIC NAME Pembrolizumab MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL Non-small cell lung cancer (NSCLC) indication: May 10, 2017 Urothelial carcinoma indication: May 18, 2017
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1 PRODUCT NAME KEYTRUDA 50 mg powder for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CAS No.: 1374853-91-4 One vial contains 50 mg of pembrolizumab. After reconstitution,
More information